These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37067232)

  • 1. Reducing fracture incidence in children with osteogenesis imperfecta: contribution of orthotics to bisphosphonates treatment.
    Eylon S; Kornitzer E; Wever C; Rigbi A; Weiss PL; Meyer S
    Disabil Rehabil; 2024 Apr; 46(7):1416-1421. PubMed ID: 37067232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
    Feehan AG; Zacharin MR; Lim AS; Simm PJ
    Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials.
    Hald JD; Evangelou E; Langdahl BL; Ralston SH
    J Bone Miner Res; 2015 May; 30(5):929-33. PubMed ID: 25407702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
    Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
    Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate therapy for osteogenesis imperfecta.
    Phillipi CA; Remmington T; Steiner RD
    Cochrane Database Syst Rev; 2008 Oct; (4):CD005088. PubMed ID: 18843680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
    Liu W; Lee B; Nagamani SCS; Nicol L; Rauch F; Rush ET; Sutton VR; Orwoll E
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1787-1796. PubMed ID: 36658750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment.
    Trejo P; Fassier F; Glorieux FH; Rauch F
    J Bone Miner Res; 2017 May; 32(5):1034-1039. PubMed ID: 28019684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials.
    Ying ZM; Hu B; Yan SG
    Orthop Surg; 2020 Aug; 12(4):1293-1303. PubMed ID: 32589343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventions for Improving Bone Mineral Density and Reducing Fracture Risk in Osteogenesis Imperfecta: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials.
    Sridharan K; Sivaramakrishnan G
    Curr Clin Pharmacol; 2018; 13(3):190-198. PubMed ID: 30160216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.
    Brunetti G; Papadia F; Tummolo A; Fischetto R; Nicastro F; Piacente L; Ventura A; Mori G; Oranger A; Gigante I; Colucci S; Ciccarelli M; Grano M; Cavallo L; Delvecchio M; Faienza MF
    Osteoporos Int; 2016 Jul; 27(7):2355-2365. PubMed ID: 26856585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
    Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
    J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
    Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
    J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Bisphosphonates on Bone Mineral Density and Fracture Rate in Patients With Osteogenesis Imperfecta: A Systematic Review and Meta-analysis.
    Shi CG; Zhang Y; Yuan W
    Am J Ther; 2016; 23(3):e894-904. PubMed ID: 25844482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta.
    Vuorimies I; Mäyränpää MK; Valta H; Kröger H; Toiviainen-Salo S; Mäkitie O
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1333-1339. PubMed ID: 28323993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteogenesis imperfecta: practical treatment guidelines.
    Antoniazzi F; Mottes M; Fraschini P; Brunelli PC; Tatò L
    Paediatr Drugs; 2000; 2(6):465-88. PubMed ID: 11127846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.